Regeneron clears key regulatory milestone, shares trade firmly on NASDAQ

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 16:58.

Regeneron Pharmaceuticals (US75886F1075) underpins its late-stage pipeline with a fresh regulatory step. The NASDAQ-listed biotech reports that the US FDA and European Medicines Agency have accepted regulatory submissions for Cemdisiran to treat generalized myasthenia gravis, according to recent company disclosures and specialist press coverage. Marketscreener summary of the Cemdisiran submissions

What the regulatory move shows

The Cemdisiran dossiers for generalized myasthenia gravis are now formally under review at both the FDA and EMA. The dual acceptance marks Cemdisiran's transition from development into the regulatory phase in two major markets, a step typically required before any approval decision can be taken. Regeneron press release on Cemdisiran filings

According to the company communication, Cemdisiran targets complement-mediated aspects of myasthenia gravis, adding to Regeneron's portfolio beyond its well-known ophthalmology and immunology franchises. Company profile overview on Marketscreener The filings follow clinical data that Regeneron has presented at recent medical meetings, though detailed timelines for potential decisions have not yet been specified in public sources.

Thursday focus on chart and valuation

On Thursday, Regeneron shares trade on NASDAQ in the mid-620 dollar range, with recent prints around 623.43 dollars as of 25 June 2026, 13:09 Eastern time, according to Dublin-based broker Davy. Davy quote page for Regeneron Pharmaceuticals The day range cited there stands between 619.27 and 631.18 dollars, indicating a relatively tight intraday band for a stock with a more than 60 billion dollar market capitalization.

Data from TradingKey place Regeneron’s market cap at roughly 66.5 billion dollars and show a trailing price-earnings ratio near 14.7, with a valuation score of 9.4 out of 10 versus 157 pharmaceutical names. TradingKey valuation overview for REGN In this framework, the shares trade materially below their recent P/E high around 29.8, positioning the stock in a mid-teens earnings multiple zone compared with large-cap peers such as AbbVie or Amgen.

The product behind the stock

Behind the Regeneron stock sits a diversified biotechnology business that generates the bulk of its revenue from monoclonal antibody therapies. A central product is Eylea, an anti-VEGF treatment for retinal diseases such as neovascular age-related macular degeneration, which has become one of the largest ophthalmology drugs globally in partnership with Bayer. Regeneron product information on Eylea Alongside Eylea, newer assets such as Dupixent in immunology and the investigational Cemdisiran in neuromuscular disease reflect the company’s strategy of focusing on high-need indications with biologic therapies.

Where the Regeneron shares trade today

Regeneron shares (US75886F1075) trade on 2026-06-25 at around 623.43 US dollars on NASDAQ, based on intraday data from Davy, with the quote reflecting a price increase of 0.87 percent versus the prior close. Davy intraday Regeneron quote

This article provides factual information on the Regeneron stock and does not contain investment advice, recommendations or solicitations to buy or sell securities. All data points are based on sources cited in the text and may change over time.